Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10245288B2 · kind B2 · utility
Inventor
Key dates
| Filing date | Dec 28, 2016 |
| Grant date | Apr 2, 2019 |
| Priority date | — |
| Expiry date | Dec 28, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K35/747
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease that involves providing an individual with an effective amount of a composition of bacteria modified using a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system so that the bacteria is able to produce a therapeutically effective amount of anti-bodies to oxidized low density lipoprotein, with the modified bacteria preferably being from the Lactobacillus, Bifidobacterium, and Streptococcus species; and most preferably including L. reuteri bacteria modified using CRISPR-Cas and/or Cpf1 systems so that it is able to survive the conditions in the duodenum and jejunum of the small intestine of a human.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.